Palatin Technologies Inc. (PTN)

[stocker25]

Met secondary endpoints.

http://www.isswshmeeting.org/isswsh2017-abstract?abstract_id=90


"Changes in the number of SSEs were not significantly different from placebo in either study; however, BMT participants reported a higher percentage of sexual encounters as satisfactory (64.4% vs 50.9% in Study 301 and 64.8% vs 47.3% in Study 302)."

"Results of this analysis of secondary endpoints support the primary results indicating that bremelanotide is efficacious on the key aspects of sexual function — desire, arousal, lubrication, and orgasm, in premenopausal women."

We should be at $2